Ira Gotliv (Lubarski)

Ira Gotliv (Lubarski) has extensive experience in the biotechnology and pharmaceutical industry. From 2016 to 2020, they worked at Pi Therapeutics, starting as a Senior Research Scientist and later becoming the Associate Director and Head of Research. In this role, they led the development of small molecules from discovery stage to pre-IND meeting with regulatory authorities, oversaw research activities, and managed a team of researchers. Ira also contributed to target protein identification, formulation development, and establishing ex-vivo systems for efficacy studies. During their tenure, they played a key role in securing series A and B funding for the company.

Prior to their time at Pi Therapeutics, Ira worked as a Senior Research Scientist at the Weizmann Institute of Science from 2013 to 2016. Here, they were involved in conceiving ideas for new projects, coordinating tasks, writing grant proposals and papers, and collaborating with scientists from various institutes.

Before that, they co-founded AE Medical in 2011, where they served as a project manager. Ira also worked as a Post Doc at the Weizmann Institute of Science from 2009 to 2011.

Recently, Ira joined Emendo Biotherapeutics in 2021 as the Director of the Proof of Concept Department, and later transitioned to the role of VP of Preclinical Research in 2022.

Throughout their career, Ira has demonstrated expertise in various areas such as preclinical studies, experimental method development, in-vivo pharmacology, ADME, TOX, PK, and dose translation studies. Ira has published research papers and has experience presenting project data to advisers, boards, and regulatory authorities.

Ira Gotliv (Lubarski) attended and completed their education at two different institutions. From 1999 to 2002, Ira studied Laboratory Medicine at Ben-Gurion University of the Negev, where they earned a B.Med.Lab.Sc. degree. After that, Ira pursued further education at Weizmann Institute of Science, focusing on Biochemistry and Molecular Biology. They completed their studies there from 2003 to 2008 and obtained a Doctor of Philosophy (Ph.D.) degree.